Published in J Lipid Res on February 03, 2017
Identifying nonpolar transbilayer helices in amino acid sequences of membrane proteins. Annu Rev Biophys Biophys Chem (1986) 11.00
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med (2010) 6.45
The helical hydrophobic moment: a measure of the amphiphilicity of a helix. Nature (1982) 5.01
A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science (2008) 4.50
Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med (2014) 4.41
The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res (1992) 3.74
Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science (1990) 3.04
Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol (1999) 2.75
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation (2000) 2.47
A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun (1970) 2.24
Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem (1994) 2.09
Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med (2014) 2.06
Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol (2010) 2.03
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med (2015) 2.03
Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest (1986) 1.96
Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation (1990) 1.89
The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem (1994) 1.89
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) (2008) 1.85
Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins. Prog Lipid Res (2004) 1.83
Interaction of an apolipoprotein (apoLP-alanine) with phosphatidylcholine. Biochemistry (1973) 1.81
Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest (1985) 1.79
Molecular basis of exchangeable apolipoprotein function. Biochim Biophys Acta (2000) 1.33
Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab (2004) 1.29
Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis (2003) 1.28
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res (2010) 1.21
Structure and dynamics of human apolipoprotein CIII. J Biol Chem (2008) 1.18
Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia. J Lipid Res (2010) 1.15
Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J Clin Invest (1991) 1.15
Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation (1994) 1.14
Apolipoprotein CIII: 42 years old and even more interesting. Arterioscler Thromb Vasc Biol (2011) 1.14
Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J Biol Chem (2013) 1.14
Surface-to-core and interparticle equilibrium distributions of triglyceride-rich lipoprotein lipids. J Biol Chem (1983) 1.10
Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr. J Lipid Res (2000) 1.10
Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. Semin Liver Dis (2013) 1.05
Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. J Lipid Res (1997) 0.99
The adsorption of biological peptides and proteins at the oil/water interface. A potentially important but largely unexplored field. J Lipid Res (2008) 0.98
Chemical synthesis and biochemical properties of peptide fragments of apolipoprotein-alanine. Proc Natl Acad Sci U S A (1973) 0.97
The N-terminal (1-44) and C-terminal (198-243) peptides of apolipoprotein A-I behave differently at the triolein/water interface. Biochemistry (2007) 0.95
Apolipoprotein C-III0 lacks carbohydrate residues: use of mass spectrometry to study apolipoprotein structure. J Lipid Res (1989) 0.94
Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production. Curr Opin Lipidol (2012) 0.93
Characterization of recombinant wild type and site-directed mutations of apolipoprotein C-III: lipid binding, displacement of ApoE, and inhibition of lipoprotein lipase. Biochemistry (2000) 0.93
C-terminus of apolipoprotein A-I removes phospholipids from a triolein/phospholipids/water interface, but the N-terminus does not: a possible mechanism for nascent HDL assembly. Biophys J (2011) 0.91
Characterization of the oligosaccharide side chain of apolipoprotein C-III from human plasma very low density lipoproteins. Biochim Biophys Acta (1978) 0.91
Oil-drop tensiometer: applications for studying the kinetics of lipase action. Methods Enzymol (1997) 0.90
Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease. Curr Opin Lipidol (2014) 0.89
Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families. Clin Genet (2013) 0.87
Modified heparin-Sepharose procedure for determination of plasma lipolytic activities of normolipidemic and hyperlipidemic subjects after injection of heparin. Clin Chem (1981) 0.86
Interfacial exclusion pressure determines the ability of apolipoprotein A-IV truncation mutants to activate cholesterol ester transfer protein. J Biol Chem (2002) 0.85
Surface behavior of apolipoprotein A-I and its deletion mutants at model lipoprotein interfaces. J Lipid Res (2013) 0.85
Lipid binding by fragments of apolipoprotein C-III-1 obtained by thrombin cleavage. Biochemistry (1977) 0.83
A novel apolipoprotein C-III variant, apoC-III(Gln38-->Lys), associated with moderate hypertriglyceridemia in a large kindred of Mexican origin. J Lipid Res (1997) 0.81
Surface pressure-dependent conformation change of apolipoprotein-derived amphipathic α-helices. J Lipid Res (2013) 0.81
Effect of the apolipoprotein C-II/C-III1 ratio on the capacity of purified milk lipoprotein lipase to hydrolyse triglycerides in monolayer vesicles. Atherosclerosis (1996) 0.80
Metabolism of apolipoproteins C-II, C-III, and B in hypertriglyceridemic men. Changes after heparin-induced lipolysis. Arteriosclerosis (1988) 0.79
Changes in helical content or net charge of apolipoprotein C-I alter its affinity for lipid/water interfaces. J Lipid Res (2013) 0.78
A Pressure-dependent Model for the Regulation of Lipoprotein Lipase by Apolipoprotein C-II. J Biol Chem (2015) 0.77
ANGPTL4 mediates shuttling of lipid fuel to brown adipose tissue during sustained cold exposure. Elife (2015) 0.88
Role of lipoprotein lipase in lipid metabolism. Curr Opin Lipidol (2016) 0.78
High Concentrations of Angiopoietin-Like Protein 4 Detected in Serum from Patients with Rheumatoid Arthritis Can Be Explained by Non-Specific Antibody Reactivity. PLoS One (2017) 0.75